Abstract

EVALUATION OF THE EFFECT OF METFORMIN ON HORMONES SERUM LEVELS IN WOMEN WITH POLYCYSTIC OVARY SYNDROME

Liqua Semean Baqer, Amina Hamed Alobaidi, Mutaz Sabah Ehmaed, Abdulghani Mohamed Alsamarai*.

ABSTRACT

Backgrpound: Polycystic ovary syndrome [PCOS] is a common reproductive problem with social and health impact. Aim: the study conducted to determine the association between body mass index and PCOS and the therapeutic effect of metformin as treatment approach. Patients and Methods: This case control prospective experimental study was carried out in Kirkuk General Hospital from January 2014 to July 2014. The recruited cases divided into three groups; Group I, 68 women with normal menstrual cycle as control group; Group II, 61 cases diagnosed as a PCOS; and Group III :- 30 cases selected from group two to receive treatment with Metformin to determine the effect of the treatment on different variables. Results: The highest percentage of PCOS (36.1%) was found in those with age group between (20-25) years. Most (65.6%) of PCOS subjects were with overweight or obese. BMI mean value was (28.81±6.68) in women with PCOS, while in control the corresponding value was (25.08±4.24). FSH, LH, and testosteron were significantly higher in women with PCOS than in control. Metformin reduced seum FSH, LH, prolactin and testosteron, with significant difference for testosteron. Conclusion: PCOS is independently associated with elevated BMI. Metformin treatment of PCOS induced significant reduction in serum testosteron, while FSH, LH and serum prolactin mean serum concentrations were reduced but not reach significant level. This warranted performance a large scale clinical trial to evalute the therapeutic effect of metformin alone or in combination with diet control approach for treatment of PCOS. These findings have implications for the pathophysiology of obesity development and management in PCOS.

Keywords: PCOS, Metform in, FSH, LH, prolactin, testosteron.